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Abstract
Background: Rhabdoid tumors (RTs) are aggressive pediatric malignancies with poor prognosis. N-(4-hydroxy
phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its
ability to down-modulate Cyclin D1. Previously, we synthesized novel halogen-substituted and peptidomimetic-
derivatives of 4-HPR that retained activity in MON RT cells. Here we analyzed the effect of 4-HPR in inhibiting the
growth of several RT, glioma, and breast cancer cell lines and tested their effect on cell cycle, apoptosis and Cyclin
D1 expression.
Methods: Effect of compounds on RT cell cycle profiles, and cell death were assessed by MTS cell survival assays
and FACS analysis. The effects of treatment on Cyclin D1 expression were determined by immunoblotting. The
efficacy of these compounds on glioma and breast cancer cell lines was also determined using MTS assays.
Results: Low micromolar concentrations of 4-HPR derivatives inhibited cell survival of all RT cells tested. The 4-HPR
derivatives altered RT cell cycle profiles and induced high levels of cell death that was correlated with their
potency. ATRA exhibited high IC50 values in all cell lines tested and did not cause cell death. In MON RT cells, the
iodo-substituted compounds were more active than 4-HPR in inducing cell cycle arrest and apoptosis. Additionally,
the activity of the compounds correlated with their ability to down-modulate Cyclin D1: while active compounds
reduced Cyclin D1 levels, inactive ATRA did not. In glioma and breast cancer cell lines, 4-HPR and 4-HPR derivatives
showed variable efficacy.
Conclusions: Here we demonstrate, for the first time, that the inhibitory activities of novel halogen-substituted and
peptidomimetic derivatives of 4-HPR are correlated to their ability to induce cell death and down-modulate Cyclin
D1. These 4-HPR derivatives showed varied potencies in breast cancer and glioma cell lines. These data indicate
that further studies are warranted on these derivatives of 4-HPR due to their low IC50s in RT cells. These derivatives
are of general interest, as conjugation of halogen radioisotopes such as
18F,
124I, or
131I to 4-HPR will allow us to
combine chemotherapy and radiotherapy with a single drug, and to perform PET/SPECT imaging studies in the
future.
Background
Rhabdoid tumors (RTs) are aggressive pediatric malig-
nancies that occur within the kidneys, soft tissues, and
central nervous system [1-4]. No standard or effective
treatment strategies are currently available for these
tumors and prognosis remains poor with a two-year sur-
vival rate of 10-25% [1,3-6]. Therefore, there is a need to
develop novel therapeutic strategies for RTs. INI1
(hSNF5, BAF47, SMARCB1) is a tumor suppressor
biallelically deleted in RTs. We have previously demon-
strated that Cyclin D1 is a key target repressed by INI1
and is required for genesis and survival of RTs in vitro
and in vivo. Furthermore, we have found that 4-HPR
e f f e c t i v e l yi n h i b i t sR Tg r o w t ha n dt h a tt h ea b i l i t yo f4 -
HPR to inhibit RTs is correlated to down-modulation of
Cyclin D1 [7,8].
4-HPR is a synthetic retinoid that is well tolerated by
humans and inhibits the growth of various cancer cells
by inducing apoptosis and, in some cases, cell cycle
arrest at various stages [9-13]. Inhibition of tumor cell
growth by 4-HPR in vitro occurs at clinically achievable
concentrations (IC50sr a n g i n gf r o m1μMt o1 5μM)
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any medium, provided the original work is properly cited.[14]. 4-HPR is largely studied as a chemo-preventive
agent in animal models of carcinogen-induced epithelial
tumors and in patients at risk for breast cancer
[10,11,15,16]. Additionally, treatment of pediatric neuro-
blastoma patients with 4-HPR has resulted in prolonged
stabilization of disease in pilot clinical studies [17-20].
4-HPR induces apoptosis in tumor cells in vitro by
v a r i o u sm e c h a n i s m si n c l u d i ng activating retinoic acid
receptors (RAR) b and g, inducing ceramide-dependent
cytotoxicity, generating free radical oxygen species,
inducing nitric oxide synthase expression resulting in
nitric oxide-dependent cytotoxicity, and increasing the
mitochondrial permeability transition [11,15,17,18,20].
4-HPR also induces cell cycle arrest likely correlated
with its ability to down-modulate proliferation-related
targets such as c-Myc, telomerase, p34/cdc2, and Cyclin
D1 [21,22]. Interestingly, over expression of Cyclin D1
sensitizes breast cancer cells to 4-HPR [23]. Based on
this information, and the fact that RTs are dependent
on Cyclin D1, we previously tested 4-HPR and found
that it inhibits the growth of RTs in vitro and in vivo in
a xenograft mouse model with efficacy correlated with
down-modulation of Cyclin D1 [7].
Several reports indicate that synthetic analogs of 4-
HPR are more active anti-tumor agents or have poten-
tially reduced toxicities compared to 4-HPR. For exam-
ple, N-benzyl hydroxyl retinamide, a non-hydrolysable
carbon-linked analog does not suppress plasma vitamin
A levels as 4-HPR does, and is therefore less toxic [24].
Additionally, conjugations of 4-HPR have exhibited
increase anti-tumor activity [25,26].
Because derivatives of 4-HPR may demonstrate more
potent biological activity, improved bioavailability, and/
or reduced toxicities compared to 4-HPR itself, we pre-
viously synthesized several novel 4-HPR derivatives
which are conjugated to halogens and other moieties,
and peptidomimetic derivatives that replace the alkene
backbone with a rigid ring structure to help increase
compound stability and bioavailability in vivo [27,28]. In
particular, the peptidomimetic derivatives are more lipo-
philic, which increases bioavailability and possibly facili-
tates crossing the blood-brain-barrier [29]. Additionally,
the derivatives that have been conjugated to halogens
may allow us to create radio-conjugates (i.e. 4-HPR con-
jugated to
18F,
124I, or
131I) that facilitate combining
radiotherapy and chemotherapy in a single agent.
In this study we examined the activity of 4-HPR deri-
vatives that we synthesized in the laboratory and tested
their activity on RT cell lines and investigated their abil-
ities to induce apoptosis, cell cycle arrest, and down-
modulate Cyclin D1. Additionally, we defined the activ-
ity profiles of these compounds in several glioma and
breast cancer cell lines, for which 4-HPR has also been
suggested as a potential chemotherapeutic agent. We
found that the 4-HPR derivatives tested potently inhib-
ited RT cell survival with efficacy correlated with down-
modulation of Cyclin D1. The derivatives tested were
also active in inhibiting the growth of several glioma
and breast cancer cell lines. Our results indicate that
because of their low IC50s and their abilities to signifi-
cantly down-modulate Cyclin D1 and induce apoptosis,
halogen-conjugated and peptidomimetic derivatives of
4-HPR are likely to be excellent diagnostic and thera-
peutic agents for RTs. Additionally, the ability of the
derivatives to significantly decrease the survival of
glioma and breast cancer cell lines indicates that they
may be of general interest for treating cancers that
respond to 4-HPR or depend on Cyclin D1 for growth.
Results and Discussion
Low micromolar concentrations of 4-HPR and its
derivatives effectively inhibit rhabdoid tumor cell growth
Our previous studies indicated that halogen-substituted
and peptidomimetic derivatives of 4-HPR have activity
against one RT cell line, namely, MON [27,28]. These
studies neither elucidated the mechanism of action of
these new compounds nor tested activities on a wide
r a n g eo fR To rn o n - R Tc e l ll i n e s .H e r ew et e s t e dt h e
efficacy of 4-HPR and highly active halogen-substituted
(5h and 5j) and peptidomimetic derivatives (11a, 11c,
and 11d) on three RT cell lines, MON, G401, and A204
(Figure 1). Since 4-HPR is derived from all trans retinoic
acid (ATRA), which is used clinically as a differentiating
and chemotherapeutic agent [30,31], we used ATRA as
a control. The three cell lines cells were treated with
increasing concentrations of indicated drugs and cell
survival was determined. We found that ATRA did not
show any activity in reducing the survival of RT cells,
indicating that this compound is not a useful candidate
for RT therapy (IC50s>5 0μM, Figure 2). 4-HPR
potently inhibited the survival of RT cells with IC50so f
0.1 μM, 2.0 μM, and 2.2 μM in G401, A204, and MON
cells respectively (Figure 2). Interestingly, iodo-deriva-
tives of 4-HPR and the peptidomimetic compound
tested, more potently decreased cell survival in MON
cells with IC50so f1 . 2μM (5j) and 1.3 μM (11d) (Figure
2A). However, the derivatives and peptidomimetic com-
pounds exhibited similar or less potent activities when
compared to 4-HPR in G401 and A204 cells. A sum-
mary of IC50s of all the compounds in these three differ-
ent RT cell lines is listed in Table 1.
Our analysis indicated that the iodo-conjugated deri-
vatives display significant potency in all RT cell lines
tested. Since iodo conjugation can potentially be used to
deliver radiotherapy and taken advantage of for radia-
tion-based imaging (by substituting with
124Io r
131I iso-
topes), these compounds are of great interest for further
study. Hence we tested the ability of these compounds
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modulate Cyclin D1 in RT cells.
Induction of cell cycle arrest in rhabdoid tumor cells lines
treated with 4-HPR and its derivatives
To determine the effect of 4-HPR derivatives on the cell
cycle profiles of RT cells we carried out FACS analysis
of cells treated with 5 or 10 μM concentrations each of
ATRA (as a control), 4-HPR, and its derivatives. ATRA
did not induce cell cycle arrest in MON, G401, or A204
cells, consistent with the observation that this drug is
not active against RT cells (Figure 3). We found that
treatment with 4-HPR and its derivatives, however,
induced complex changes in the cell cycle profiles of
these cells. In MON cells, 4-HPR slightly increased the
percentage of cells in S-phase, while both iodo-deriva-
tives induced significant S-phase cell cycle arrest (P =
0.0057 for 5 μM 5j, P < 0.0001 for 10 μM 5j, P = 0.001
for 5 μM 11d, and P < 0.0001 for 10 μM 11d) (Figure
3A). Similarly, in G401 cells, 4-HPR increased the per-
centage of cells in S-phase at both 5 μMa n d1 0μM;
however, S-phase arrest was only statistically significant
at 10 μM( P = 0.006) (Figure 3B). The 4-HPR derivatives
induced varying stages of cell cycle arrest in G401 cells:
(i) 5 μM 5j induced G2-arrest (P = 0.004), (ii) 5 μM 11d
induced G1-arrest (P < 0.0001), and (iii) 10 μM 11d
induced S-arrest (P = 0.0003) (Figure 3B). In A204 cells
4-HPR caused G2-arrest at 5 μM (P = 0.0004) and S-
arrest at 10 μM (P = 0.0024) (Figure 3C). Similarly to 4-
HPR, 10 μM 11d induced S-arrest in A204 cells (P =
0.0016) (Figure 3C). In general, 4-HPR and its deriva-
tives showed a tendency to significantly alter the cell
cycle profiles of RT cells. Our results are consistent with
previous observations of 4-HPR in other cancer cells,
Figure 1 Chemical structures of ATRA, 4-HPR, and 4-HPR derivatives and peptidomimetics: A. ATRA, B. 4-HPR, C and D. 4-HPR derivatives,
5h (C) and 5j (D). E-G. 4-HPR peptidomimetics, 11a (E), 11c (F), and 11d (G).
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phase [9,12,13].
Induction of apoptosis in rhabdoid tumor cells by 4-HPR
and 4-HPR derivatives and peptidomimetics
Though the nature of induction of cell-cycle arrest by 4-
HPR and its derivatives varied from cell type to cell
type, fluorescence activated cell sorting (FACS) analysis
indicated that cell death, as measured by the percentage
of cells in Sub G1/G0 stage, significantly and consis-
tently increased in response to treatment in all cell lines
tested. As expected, ATRA did not cause a significant
increase in the percentage of sub-G1 cells above the
background in MON and G401, but slightly increased
the sub-G1 cells in A204 cells (P = 0.0076 at 5 μMa n d
P = 0.0079 at 10 μM) (Figure 4A-C). On the other
hand, 4-HPR and the iodo-conjugated derivatives (5j
and 11d) significantly induced cell death in all 3 cells
lines (P < 0.0001 for all drug treatment in all cells lines,
except for 5 μM 11d in G401 cells with P = 0.0085)
(Figure 4A-C). The level of cell death induced by the
iodo-derivatives was similar to that induced by 4-HPR
in MON cells (Figure 4A). In both G401 and A204 cells,
however, the iodo-derivatives induced lower levels of
cell death than did 4-HPR, consistent with the slightly
increased IC50 values of the compounds in these 2 cell
lines (Figure 4B and 4C). Taken together, our results
indicated that 4-HPR and its iodo-conjugated derivatives
induced cytotoxicity was correlated with their ability to
stimulate high levels of cell death.
Correlation of the activity of 4-HPR, 4-HPR derivatives
and peptidomimetics to down-modulation of Cyclin D1 in
RT cells
Our previous studies indicat e dt h a tR T sa r ee x q u i s i t e l y
dependent on Cyclin D1 for their genesis and survival in
vitro and in vivo [32]. Furthermore, the activity of 4-
HPR in various cancer cell lines has been correlated
with its ability to down-modulate Cyclin D1
[7,21,23,33]. Previous studies within our laboratory have
also shown that the efficacy of 4-HPR in RT cells was
correlated with down-modulation of Cyclin D1 [7]. For
this reason, we sought to determine whether or not the
inhibitory activities of 4-HPR derivatives were correlated
with their ability to down-modulate Cyclin D1, and if
the increased potency of some derivatives in MON cells
could be explained by their improved ability to decrease
Cyclin D1 levels. To test this, we carried out immuno-
blot analysis of whole cell lysates from MON cells
before and after treatment with ATRA, 4-HPR, 5h, 5j,
and 11d. We found that the efficacy of each compound
was correlated with the ability to down-modulate Cyclin
D1 protein levels. ATRA, as expected, did not decrease
Cyclin D1 (Figure 5A and 5B). 4-HPR, which inhibits
the survival of RT cells, caused a reduction in Cyclin D1
levels at 10 μM concentrations (Figure 5A and 5B). 4-
HPR derivatives and peptidomimetics, which also exhib-
ited IC50si nt h el o wm i c r o m o l a r - r a n g ew e r ea b l et o
down-modulate Cyclin D1 levels significantly, at both 5
and 10 μM concentrations, decreasing Cyclin D1 to
undetectable levels at 10 μM (Figure 5A and 5B). These
results indicated that the 4-HPR derivatives down-
Figure 2 Inhibition of RT cell growth by 4-HPR and its
derivatives and peptidomimetics: Survival curves of MON (A),
G401 (B) and A204 (C) cells treated for three days with increasing
concentrations of ATRA, 4-HPR, the most active halogen substituted
derivative of 4-HPR (5h and 5j) and peptidomimetic compounds
(11a, 11c and 11d).
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cells showing that the chemical alterations made in the
derivatives do not alter their ability to inhibit Cyclin D1.
Inhibition of glioma and breast cancer cell growth by 4-
HPR and 4-HPR derivatives and peptidomimetics
The activity of 4-HPR in glioma and breast cancer cell
lines has been studied previously and 4-HPR has been
indicated as a potential therapeutic for these 2 types of
cancers [23,34-38]. In particular, 4-HPR has been impli-
cated for use as a chemo-preventive agent for people at
risk for breast cancer [10,16,39,40]. Additionally, many
breast cancers and gliomas over-express Cyclin D1
[41,42]. We performed immunoblot analysis to deter-
mine the relative expression levels of Cyclin D1 in the
glioma (SF268, U251, and U87) and breast cancer
(MDAMB231 and MCF7) cell lines, when compared to
RT cell lines such as MON. All cell lines tested
expressed high levels of Cyclin D1; in some cases the
level of Cyclin D1 was even higher than that found in
MON RT cells (Figure 6A and 7A).
We tested the efficacy of 4-HPR derivatives in these
glioma and breast cancer cell lines by treating cells with
various concentrations of drugs for 3 days. We found
that ATRA did not reduce the survival of these cells at
concentrations of 50 μM and lower (Figures 6B-D and
7B and 7C). 4-HPR inhibited the growth of all glioma
and breast cancer cell lines tested with IC50sr a n g i n g
from 0.4 to 6.9 μM, suggesting that RT cells are more
sensitive to 4-HPR than glioma and breast cancer cells.
In general, the derivatives of 4-HPR were less effective
than parent 4-HPR in inhibiting the growth of these
non-RT cells. IC50s of the compounds in glioma and
breast cancer cells ranged from 0.4 μM to 23.0 μMa n d
are presented in Table 1.
Conclusions
Our report demonstrates that low micromolar concen-
trations of halogen-substituted 4-HPR derivatives and
peptidomimetics inhibit the growth of several RT cell
Table 1 IC50 values for ATRA, 4-HPR, and derivatives on various tumor cell lines
IC50 (μM)
Tumor type Cell lines Rhabdoid Glioma Breast
MON G401 A204 SF268 U87 U251 MCF7 MDAMB231
ATRA > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
4-HPR 2.2 0.1 2.0 6.9 5.0 1.4 2.2 0.4
5h 3.6 0.3 1.7 18.9 16.3 5.8 6.3 N/A*
5j 1.2 3.0 8.2 12.0 13.7 9.1 11.8 23
11a 1.9 0.2 4.4 10.4 5.0 2.4 8.3 2.3
11c 5.2 0.3 5.6 15.7 9.3 5.9 12.1 5.3
11d 1.3 3.2 7.5 3.8 9.4 7.8 8.2 12.0
*The IC50 could not be determined because the survival curve was not sigmoidal
Figure 3 Induction of cell cycle arrest by 4-HPR and its
derivatives and peptidomimetics: A-C. Cell cycle profile of MON
(A), G401 (B), and A204 (C) cells treated for three days with 5 μMo r
10 μM concentrations of ATRA, 4-HPR, and the iodo-conjugated 4-
HPR derivative (5j) and peptidomimetic (11d).
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suggests that these derivatives of 4-HPR retain the activ-
ity and, in some cases, improve potency. Treatment with
4-HPR, 5j, and 11d induced varied effects on the cell
cycle in the three RT cell lines. This variability was not
surprising: many studies have shown that 4-HPR alters
the cell cycle profiles of tumor cells in complex ways,
inducing G1,G 2, and S phase cell cycle arrest under dif-
ferent conditions [9,12,13]. In addition to cell cycle
arrest, 4-HPR and both of the iodo-derivatives induced
high levels of cell death in all RT cell lines tested. The
most dramatic induction of cell death occurred in G401
cells, in which both 5 μMa n d1 0μM concentrations of
all compounds induced approximately 90% cell death.
These results indicate that the efficacies of these drugs
are most closely correlated with their abilities to induce
cell death than their ability to induce cell cycle arrest.
Additionally, the efficacy of the compounds in MON RT
cells was correlated with potent down-modulation of
Cyclin D1.
It is important to note that parent compound ATRA
did not show significant activity in any of the tumor
cells tested, rhabdoid or otherwise. Correspondingly,
ATRA treatment did not result in cell cycle arrest,
enhanced cell death, or down-modulation of Cyclin D1
in RT cells. ATRA is an FDA-approved compound and
is clinically used to treat some cancers including pro-
myelocytic leukemia [30,31]. Unfortunately, our results
suggest that ATRA is not a possible therapeutic for
treatment of RTs.
Since 4-HPR has been indicated as a potential thera-
peutic for both gliomas and breast cancers [23,34-38],
we also tested the efficacy of these derivatives in several
glioma and breast cancer cell lines. Parent compound
ATRA, did not reduce survival of these cell types, while
4-HPR was able to reduce their survival with IC50’sr a n -
ging from 0.4 μMt o6 . 9μM. Interestingly, in both
glioma and breast tumor cell lines tested, 4-HPR was
more potent than derivatives 5j and 11d, with the excep-
tion of compound 11d in SF268 glioma cells, which was
more (1.8-fold) potent in inducing cell death compared
to 4-HPR. However, it is interesting to note that, in
Figure 4 Induction of cell death by 4-HPR and its derivatives
and peptidomimetics: A-C. Percentage of MON (A), G401 (B), and
A204 (C) cells at sub- G1 when treated for three days with 5 μMo r
10 μM concentrations of ATRA, 4-HPR, and the iodo-conjugated 4-
HPR derivative (5j) and peptidomimetic (11d).
Figure 5 Effects of 4-HPR and its derivatives and
peptidomimetics on Cyclin D1 expression in MON cells: A and
B. Immunoblot analysis to determine the effect of 5 μM and 10 μM
concentrations ATRA, 4-HPR, and 4-HPR derivatives and
peptidomimetics on Cyclin D1 expression. GAPDH is used as a
loading control.
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tive to 4-HPR compared to RT cells.
There are several reports indicating that derivatives of 4-
HPR show similar or increased anti-tumor activity and, in
some cases, show decreased toxicities [24,25,43]. A non-
hydrolysable carbon-linked analogs of 4-HPR, N-benzyl
Figure 6 Inhibition of glioma cell growth by 4-HPR and its
derivatives and peptidomimetics: A. Immunoblot analysis to
determine the levels of Cyclin D1 protein expression in glioma cell
lines compared to MON RT cells. B-D. Survival curves of SF268 (B),
U87 (C), and U251 (D) glioma cells treated for three days with
increasing concentrations of ATRA, 4-HPR, and 4-HPR derivatives
and peptidomimetics.
Figure 7 Inhibition of breast cancer cell growth by 4-HPR and
its derivatives and peptidomimetics. A. Immunoblot analysis to
determine the levels of Cyclin D1 protein expression in the breast
cancer cell lines tested compared to MON RT cells. B and C. Survival
curves of MCF7 (B) and MDAMB231 (C) cells treated for three days
with increasing concentrations of ATRA, 4-HPR, and 4-HPR
derivatives and peptidomimetics.
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levels as 4-HPR does and is therefore less toxic [24]. Gly-
cosyl conjugates of 4-HPR have exhibited increased anti-
tumor activity [25]. One of the metabolite of 4-HPR, 4-
oxo-fenretinide, exhibited increased potency in causing
G2-M arrest [26]. However, the compounds that we
describe here are halogen conjugated and peptidomimetic
compounds derived from 4-HPR. Our previous report, for
the first time, described the synthesis and identification of
these halogen-substituted and peptidomimetic derivatives
of 4-HPR [27,28]. We sought to create derivatives of 4-
HPR that are at least as active as 4-HPR itself in killing RT
cells, but that are also amenable for further modification
such as conjugation of radioactive moieties or nanoparti-
cles. We believe that conjugation of radioactive moieties
or nanoparticles are likely to increase the therapeutic
potential of 4-HPR but might also lead to development of
compounds for use in imaging diagnostic studies. To facil-
itate such development, we designed and tested several
halogen-conjugated derivatives of 4-HPR [27].
Previous reports from our laboratory indicated that 4-
HPR derivatives are indeed active against MON RT
cells. The data presented in this report indicate that the
halogen-substituted derivatives and peptidomimetic deri-
vatives of 4-HPR are active against a variety of cancer
cells. Furthermore, we find that the activities of these
compounds are correlated to their ability to induce
potent cell death and down-modulation of Cyclin D1
expression. These data are consistent with the idea that
4-HPR can be further modified to create therapeutic
compounds that are more stable and are likely to have
better bioavailability profiles. In addition, the fact that
halogen-derivatives of 4-HPR retain their activity sug-
gests that conjugating 4-HPRt or a d i o a c t i v eh a l o g e n s
w i l lb eav a l u a b l ec l i n i c a lt o o l .M o d i f y i n gt h ec u r r e n t
derivatives to contain radioactive halogens, such as
18F,
124I, or
131I may allow us to use these compounds as
imaging agents using positron emission tomography
(PET) and as agents to deliver combined chemotherapy
and radiotherapy. Radioactive derivatives can also be
used to evaluate bioavailability of 4-HPR in vivo, using
non-invasive imaging. In addition, the peptidomimetic
derivatives of 4-HPR (11a, 11c, and 11d) may be more
stable and may have the potential to traverse the blood-
brain barrier because of the substitution of the alkene
backbone with a lipophilic ring structure. Because of
these reasons, and because of the relatively high toler-
ance and low toxicity of 4-HPR, we propose that further
studies on these 4-HPR derivatives are warranted.
Methods
Cell culture and drugs
The RT cell lines used, MON [44], G401 (American
Type Culture Collection), and A204 (American Type
Culture Collection) were maintained in RPMI supple-
mented with 10% fetal bovine serum, 50 U/mL penicil-
lin, 50 μg/mL streptomycin, and 2 mM L-glutamine.
Cell plating and drug treatment was performed in RPMI
supplemented with 10% charcoal/dextran-adsorbed fetal
bovine serum (HyClone), 50 U/mL penicillin, 50 μg/mL
streptomycin, and 2 mM L-glutamine.
Glioma cell lines SF268, U87, and U251 and breast
cancer cell lines MCF7 and MDAMB231 were main-
tained in DMEM supplemented with 10% fetal bovine
serum, 50 U/mL penicillin, 50 μg/mL streptomycin, and
2 mM L-glutamine. Cell plating and drug treatment was
performed in DMEM supplemented with 10% charcoal/
dextran-adsorbed fetal bovine serum (HyClone), 50 U/
mL penicillin, 50 μg/mL streptomycin, and 2 mM L-
glutamine.
Stock solutions of all drugs were prepared at 10 mM
concentration in 100% ethanol. Working solutions were
prepared by diluting the stocks into cell culture medium
so that the final concentration of ethanol remained con-
stant in all wells of each assay. 4-HPR was purchased
from ONBIO (CAS# 65646-68-6) and all derivatives
were synthesized by the author Dr. Bhaskar C. Das as
previously described [27,28].
Cell survival methyl tetrazolium salt (MTS) assays
Aliquots of 8 × 10
3 cells/well were plated in 96-well
plates for all cell types except for G401, which were pla-
ted at 6.5 × 10
3 cells/well and treated with serial dilu-
tions of drugs for three days. Cell survival was
determined using an MTS assay kit (CellTiter 96 Aqu-
eous One Solution Cell Proliferation Assay Kit;
Promega).
Cell cycle profile and cell death analysis
Propidium iodide staining and FACS analysis was per-
formed as previously described [45]. CellQuest Pro soft-
ware (BD Biosciences) was used to elaborate data.
Analysis of cell death was performed by gating for the
sub-G1 population during FACS as previously described
[7].
Statistical analysis
Statistical analysis of the data was performed using
GraphPad Prism (San Diego, CA). T-tests and/or one-
way ANOVA were used to analyze differences in cell
cycle profiles and induction of cell death. Relative IC50
values for survival data were calculated using the non-
linear regression curve fit with sigmoidal dose response
(variable slope) function. Relative IC50 is the concentra-
tion giving a response exactly halfway between the fitted
top and bottom of the survival curve when graphed as
percent inhibition versus the log of compound
concentration.
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Immunoblot analysis was carried out using a-Cyclin D1
(Thermo Scientific, Catalog#MS-210) and a-GAPDH
(Chemicon International, Catalog#MAB374). Chemilu-
minescence detection was achieved using SuperSignal
West Pico and Femto Chemiluminescence Substrate for
GAPDH and Cyclin D1 respectively [Pierce, Cata-
log#34080 (Pico) or #34095 (Femto)].
Abbreviations
4-HPR: N-(4-hydroxyphenyl)retinamide; ANOVA: analysis of variance; ATRA:
All-trans retinoic acid; DMEM: Dulbecco’s modified Eagle’s medium; FACS:
Fluorescence activated cell sorting; FDA: Food and Drug Administration;
IC50: half maximal inhibitory concentration; MTS: methyl-tetrazolium salt;
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